Anzeige
Mehr »
Login
Sonntag, 03.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Technischer Ausbruch: Diese Kupferaktie ist in den letzten 52 Wochen um 300 % gestiegen! Der Durchbruch läuft!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 929183 | ISIN: FI0009008098 | Ticker-Symbol: 0BE
Frankfurt
01.11.24
12:48 Uhr
0,291 Euro
+0,005
+1,75 %
Branche
Dienstleistungen
Aktienmarkt
Sonstige
1-Jahres-Chart
DOVRE GROUP OYJ Chart 1 Jahr
5-Tage-Chart
DOVRE GROUP OYJ 5-Tage-Chart
RealtimeGeldBriefZeit
0,2950,34102.11.
GlobeNewswire (Europe)
118 Leser
Artikel bewerten:
(0)

Dovre Group Plc: Dovre Group's Half-year Financial Report 1.1.-30.6.2024

Dovre Group Plc Half-year financial statement August 15, 2024, at 9:00 a.m.

DOVRE GROUP'S HALF-YEAR FINANCIAL REPORT 1.1.-30.6.2024

The figures presented in this half-year financial report are not audited. Last year's corresponding period in parentheses. The Renewable Energy segment, consisting of the operations of the windmill park construction and construction design company Suvic Oy is fully consolidated in the Group's financial statements. The non-controlling interest (49%) is presented as a separate line item in the income statements and balance sheet.

April-June 2024

  • Net sales increased 7,5% to EUR 50.9 (47.3) million
    • Project Personnel: net sales EUR 25.3 (25.9) million - decrease of 2.4%.
    • Consulting: net sales EUR 3.5 (4.0) million - decrease of 13.0%
    • Renewable Energy: net sales EUR 22.1 million (17.4) - increase of 26.9 %
  • EBITDA EUR 2.1 (1.8) million - increase of 19.7%
  • Operating profit EUR 1.9 (1.5) million - increase of 25.7 %
  • Profit before tax EUR 1.7 (1.3) million - increase of 30.2 %
  • Earnings for the shareholders of the parent company EUR 1.0 (0.8) million - increase of 32.8%
  • Earnings per share EUR 0.010 (0.007).
  • Net cash flow from operating activities EUR 1.6 (2.9) million.

January-June 2024

  • Net sales decreased by 0.1% to EUR 93.2 (93.1) million.
    • Project Personnel: net sales EUR 50.5 (50.7) million - a decrease of 0.4%.
    • Consulting: net sales EUR 7.1 (9.0) million - a decrease of 22.3%.
    • Renewable Energy: net sales EUR 35.6 (33.3) million - an increase of 6.9%.
  • EBITDA was EUR 2.5 million negative (EUR 3.7 million positive)
  • Operating result was EUR 3.0 million negative (EUR 3.2 million positive)
  • Profit before tax was EUR 3.3 million negative (EUR 2.8 million positive)
  • Earnings for the shareholders of the parent company were EUR 1.4 million negative (EUR 1.8 million positive)
  • Earnings per share were EUR -0,013 (0.017).
  • Net cash flow from operating activities was EUR -0.3 (7.1) million.

Dovre Group's profitability for the period was clearly negative due to a significant write-down (5.8 million euros) of a single Renewable Energy project in Q1. The project was technically successful but exceeded the cost budget considerably. Corrective actions have been taken and Suvic expects the remainder of 2024 to clearly exceed the comparison period of 2023 in both revenue and EBIT.

Outlook for 2024 unchanged (issued on 18 April 2024)

Dovre Group's net sales in 2024 are expected to be in the range of 185 to 210 million euros and the operating profit (EBIT) is expected to be in the range of 2 to 4 million euros.

CEO ARVE JENSEN:

The start of the year 2024 was particularly challenging due to a significant write- down in one of our Renewable Energy projects - undertaken by our subsidiary, Suvic Oy. Apart from this setback, the remainder of Dovre Group's operations have progressed in line with our expectations.

In the Renewable Energy segment, Suvic has commenced work on two new wind farm projects in Sweden and a Heat Pump plant for Fortum. In addition, Dovre Group has joined a renewable energy consortium in Pyhäsalmi, which encompasses three separate projects. Our initial commitment is to participate in the development of an 85 MW Battery Energy Storage System (BESS), adjacent to the former Pyhäsalmi copper and zinc mine. Our project development company, Renetec, is also evaluating several early-stage solar projects for further development.

In Project Personnel, the sales have remained strong and are on par with record highs from the previous year. Meanwhile, growth in both EMEA and Singapore has offset the reduction in North American sales following the completion of a big renewable energy project. However, profitability has decreased compared to the previous year, owing to a shift in our project and client portfolio.

In Consulting, the Norwegian market has been less active than last year. The effects of new temporary hiring legislation, which took effect last year, have had a limited impact on the energy sector's activity level thus far. On the other hand, the public sector in Norway has been more noticeably affected, slowing down hiring processes. Furthermore, there has been a decline in public investments across civil construction, transport and ICT. The Finnish market has remained stable, with both the Proha and eSite businesses developing as planned.

We also started the next phase of our sustainability reporting program, aligning them with the new CSRD reporting requirements to ensure that we continue to create value through sustainable practices.

Looking ahead, we recognize that uncertainties persist in the global market. Nevertheless, we anticipate strong demand for our services in the second half of the year. In addition, we are proactively implementing measures to enhance operational efficiency and drive sustainable profitability.

GROUP'S KEY FIGURES

EUR million4-6
2024
4-6
2023
Change
%
1-6
2024
1-6
2023
Change
%
1-12
2023
Net sales50.947.37.593.293.10.1%196.7
EBITDA2.11.818.7 %-2.53.7 8.4
% of net sales 4.1 %3.7 % -2.7 %4.0 % 4.3%
Operating result1.91.523.8 %-3.03.2 7.4
% of net sales 3.6 %3.2 % -3.2 %3.4 % 3.8 %
Profit before taxes1.71.330.2-3.32.8 6.3
% of net sales3.3 %2.8 % -3.5 %3.0 % 3.2 %
Earnings for the shareholders of the parent company1.00.832.8 %-1.41.8 4.1
% of the net sales2.0 %1.6 % -1.5 %1.9 % 2.1 %
Net cash flow from operating activities1.62.9-45.4 %-0.37.1 0.1
Net debt3.8-6.4 3.8-6.4 1.2
Debt-equity ratio (Gearing), %11.6 %-18.5 % 11.6 %-18,5% 3.1 %
Earnings per share, EUR
Undiluted0.0100.00732.8 %-0.0130.017 0.038
Diluted0.0100.00732.8 %-0.0130.017 0.038

This stock exchange release is a summary of Dovre Group Plc's Half-Year Financial Report January 1 - June 30, 2024. The full bulletin is attached to this release and is also available online at www.dovregroup.com-> Investors

Espoo, August 15, 2024

DOVRE GROUP PLC
BOARD OF DIRECTORS

For additional information, please contact:

Dovre Group PLC

Arve Jensen, CEO
arve.jensen@dovregroup.com
tel. +47 90 60 78 11

Hans Sten, CFO
hans.sten@dovregroup.com
tel. +358 20 436 2000

Financial reporting in 2024

Dovre Group releases its Q3 trading statement for January 1 - September 30, 2024, on Thursday, October 24, 2024.

Distribution
Nasdaq Helsinki Ltd
Major media
www.dovregroup.com

The figures presented in this half-year financial report are not audited.


© 2024 GlobeNewswire (Europe)
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.